Exscientia looks inward

How Exscientia plans to use $26M B round to build out AI-driven pipeline

After spending six years building its artificial intelligence drug discovery platform and working with pharma partners, Exscientia Ltd. aims to use the bulk of the $26 million raised in a series B round to build its own internal therapeutics pipeline.

CEO Andrew Hopkins

Read the full 434 word article

User Sign In